Trial
NCT01319539
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Estrogen Receptor Negative
Intervention
Akt Inhibitor MK2206
Why stopped
terminated early, due to toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-08-30